225 related articles for article (PubMed ID: 26606459)
1. Effect of Gene Expression Classifier Molecular Testing on the Surgical Decision-Making Process for Patients With Thyroid Nodules.
Noureldine SI; Olson MT; Agrawal N; Prescott JD; Zeiger MA; Tufano RP
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1082-8. PubMed ID: 26606459
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Effect of Diagnostic Molecular Testing on the Surgical Decision-Making Process for Patients With Thyroid Nodules.
Noureldine SI; Najafian A; Aragon Han P; Olson MT; Genther DJ; Schneider EB; Prescott JD; Agrawal N; Mathur A; Zeiger MA; Tufano RP
JAMA Otolaryngol Head Neck Surg; 2016 Jul; 142(7):676-82. PubMed ID: 27196108
[TBL] [Abstract][Full Text] [Related]
3. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
4. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules.
Wu JX; Young S; Hung ML; Li N; Yang SE; Cheung DS; Yeh MW; Livhits MJ
Thyroid; 2016 Jul; 26(7):916-22. PubMed ID: 27161519
[TBL] [Abstract][Full Text] [Related]
5. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
[No Abstract] [Full Text] [Related]
6. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
[No Abstract] [Full Text] [Related]
7. Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience.
Vora A; Holt S; Haque W; Lingvay I
Otolaryngol Head Neck Surg; 2020 May; 162(5):634-640. PubMed ID: 32182188
[TBL] [Abstract][Full Text] [Related]
8. Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules.
Marti JL; Avadhani V; Donatelli LA; Niyogi S; Wang B; Wong RJ; Shaha AR; Ghossein RA; Lin O; Morris LG; Ho AS
Ann Surg Oncol; 2015 Nov; 22(12):3996-4001. PubMed ID: 25862581
[TBL] [Abstract][Full Text] [Related]
9. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
10. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
11. Clinical diagnostic gene expression thyroid testing.
Steward DL; Kloos RT
Otolaryngol Clin North Am; 2014 Aug; 47(4):573-93. PubMed ID: 25041959
[TBL] [Abstract][Full Text] [Related]
12. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
[TBL] [Abstract][Full Text] [Related]
13. Multicenter clinical experience with the Afirma gene expression classifier.
Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
Geng Y; Aguilar-Jakthong JS; Moatamed NA
Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
[TBL] [Abstract][Full Text] [Related]
15. Impact of a gene expression classifier on the long-term management of patients with cytologically indeterminate thyroid nodules.
Singer J; Hanna JW; Visaria J; Gu T; McCoy M; Kloos RT
Curr Med Res Opin; 2016 Jul; 32(7):1225-32. PubMed ID: 26973059
[TBL] [Abstract][Full Text] [Related]
16. Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis.
Santhanam P; Khthir R; Gress T; Elkadry A; Olajide O; Yaqub A; Driscoll H
Med Oncol; 2016 Feb; 33(2):14. PubMed ID: 26749587
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules.
Polavarapu P; Fingeret A; Yuil-Valdes A; Olson D; Patel A; Shivaswamy V; Matthias TD; Goldner W
J Endocr Soc; 2021 Nov; 5(11):bvab148. PubMed ID: 34708178
[TBL] [Abstract][Full Text] [Related]
18. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
19. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
20. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules.
Wu JX; Lam R; Levin M; Rao J; Sullivan PS; Yeh MW
Surgery; 2016 Jan; 159(1):118-26. PubMed ID: 26435428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
